Benzinga | Nov 2, 2020 04:04PM EST

Esperion Therapeutics Q3 EPS $(3.07) Beats $(3.41) Estimate, Sales $3.80M Miss $5.93M Estimate

Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(3.07) per share which beat the analyst consensus estimate of $(3.41) by 9.97 percent. This is a 21.83 percent decrease over losses of $(2.52) per share from the same period last year. The company reported quarterly sales of $3.80 million which missed the analyst consensus estimate of $5.93 million by 35.92 percent. This is a 287.36 percent increase over sales of $981.00 thousand the same period last year.